Luciano J Costa, Professor at University of Alabama at Birmingham, shared a post on X:
“A lot in multiple myeloma at ASCO.
JNJ-5322 is likely the greatest innovation we have seen in a few years.
Potential to disrupt our approach to immunotherapy even before we figure out the current players.
Congratulations to the investigators.”
More posts featuring ASCO25.